Evoke Pharma (NASDAQ:EVOK) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a report issued on Wednesday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Performance

EVOK opened at $4.37 on Wednesday. The company has a market capitalization of $6.50 million, a P/E ratio of -0.40 and a beta of 0.15. The company has a 50-day moving average of $4.52 and a 200-day moving average of $5.06. Evoke Pharma has a 1-year low of $3.54 and a 1-year high of $12.32.

Hedge Funds Weigh In On Evoke Pharma

An institutional investor recently bought a new position in Evoke Pharma stock. Corsair Capital Management L.P. purchased a new position in Evoke Pharma, Inc. (NASDAQ:EVOK) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned about 1.42% of Evoke Pharma at the end of the most recent quarter.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.